Danaher Corporation (NYSE:DHR) – Research analysts at Jefferies Group boosted their FY2017 earnings per share estimates for shares of Danaher Corporation in a report released on Friday. Jefferies Group analyst B. Couillard now anticipates that the conglomerate will post earnings of $3.99 per share for the year, up from their previous forecast of $3.95. Jefferies Group currently has a “Buy” rating and a $95.00 target price on the stock. Jefferies Group also issued estimates for Danaher Corporation’s Q4 2017 earnings at $1.14 EPS, Q3 2018 earnings at $1.07 EPS and FY2018 earnings at $4.35 EPS.

Danaher Corporation (NYSE:DHR) last released its earnings results on Thursday, October 19th. The conglomerate reported $1.00 EPS for the quarter, topping analysts’ consensus estimates of $0.95 by $0.05. Danaher Corporation had a net margin of 13.36% and a return on equity of 11.48%. The business had revenue of $4.53 billion for the quarter, compared to the consensus estimate of $4.47 billion. During the same period in the previous year, the firm earned $0.87 EPS. The business’s revenue for the quarter was up 9.6% on a year-over-year basis.

ILLEGAL ACTIVITY WARNING: “Danaher Corporation Expected to Post FY2017 Earnings of $3.99 Per Share (DHR)” was first posted by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/10/23/danaher-corporation-expected-to-post-fy2017-earnings-of-3-99-per-share-dhr.html.

A number of other research analysts also recently issued reports on DHR. BidaskClub downgraded shares of Danaher Corporation from a “hold” rating to a “sell” rating in a research report on Saturday, July 8th. Royal Bank Of Canada restated a “hold” rating and set a $88.00 target price on shares of Danaher Corporation in a research report on Wednesday, July 12th. Zacks Investment Research downgraded shares of Danaher Corporation from a “hold” rating to a “sell” rating in a research report on Wednesday, July 12th. Wells Fargo & Company started coverage on shares of Danaher Corporation in a research report on Thursday, July 13th. They set a “market perform” rating and a $90.00 target price on the stock. Finally, Citigroup Inc. set a $96.00 target price on shares of Danaher Corporation and gave the company a “buy” rating in a research report on Friday, July 21st. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $93.31.

Shares of Danaher Corporation (DHR) opened at 90.79 on Monday. Danaher Corporation has a 12-month low of $76.27 and a 12-month high of $91.64. The company has a 50 day moving average of $86.59 and a 200-day moving average of $84.29. The company has a market capitalization of $63.07 billion, a P/E ratio of 28.98 and a beta of 1.03.

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Friday, September 29th will be paid a dividend of $0.14 per share. The ex-dividend date is Thursday, September 28th. This represents a $0.56 annualized dividend and a dividend yield of 0.62%. Danaher Corporation’s dividend payout ratio is currently 16.52%.

In other news, insider Thomas Patrick Joyce, Jr. sold 9,772 shares of the firm’s stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $81.78, for a total transaction of $799,154.16. Following the completion of the transaction, the insider now directly owns 155,520 shares of the company’s stock, valued at approximately $12,718,425.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider William King sold 43,688 shares of the firm’s stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $82.86, for a total transaction of $3,619,987.68. Following the transaction, the insider now directly owns 45,748 shares of the company’s stock, valued at $3,790,679.28. The disclosure for this sale can be found here. 12.20% of the stock is owned by company insiders.

Large investors have recently added to or reduced their stakes in the stock. GQG Partners LLC bought a new position in shares of Danaher Corporation in the second quarter valued at $101,000. Proficio Capital Partners LLC grew its stake in shares of Danaher Corporation by 92.3% in the first quarter. Proficio Capital Partners LLC now owns 1,246 shares of the conglomerate’s stock valued at $105,000 after buying an additional 598 shares in the last quarter. Monetary Management Group Inc. grew its stake in shares of Danaher Corporation by 10.7% in the second quarter. Monetary Management Group Inc. now owns 1,550 shares of the conglomerate’s stock valued at $131,000 after buying an additional 150 shares in the last quarter. Acrospire Investment Management LLC grew its stake in shares of Danaher Corporation by 185.5% in the second quarter. Acrospire Investment Management LLC now owns 1,693 shares of the conglomerate’s stock valued at $143,000 after buying an additional 1,100 shares in the last quarter. Finally, ClariVest Asset Management LLC bought a new position in shares of Danaher Corporation in the first quarter valued at $157,000. 75.66% of the stock is owned by institutional investors and hedge funds.

Danaher Corporation Company Profile

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Earnings History and Estimates for Danaher Corporation (NYSE:DHR)

Receive News & Ratings for Danaher Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher Corporation and related companies with MarketBeat.com's FREE daily email newsletter.